PH26367A - Topical preparation for treating otopathy - Google Patents
Topical preparation for treating otopathy Download PDFInfo
- Publication number
- PH26367A PH26367A PH38446A PH38446A PH26367A PH 26367 A PH26367 A PH 26367A PH 38446 A PH38446 A PH 38446A PH 38446 A PH38446 A PH 38446A PH 26367 A PH26367 A PH 26367A
- Authority
- PH
- Philippines
- Prior art keywords
- ofloxacin
- group
- solution
- otopathy
- oflx
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000000699 topical effect Effects 0.000 title claims description 10
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 50
- 229960001699 ofloxacin Drugs 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 19
- 210000000959 ear middle Anatomy 0.000 description 13
- 210000004877 mucosa Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010033072 otitis externa Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000002768 hair cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000004049 perilymph Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 3
- 206010033109 Ototoxicity Diseases 0.000 description 3
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000003477 cochlea Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000000613 ear canal Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 hydrochloric acid Chemical class 0.000 description 3
- 210000000067 inner hair cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 231100000262 ototoxicity Toxicity 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003454 tympanic membrane Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 210000003030 auditory receptor cell Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001098 no ototoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63086378A JPH01258620A (ja) | 1988-04-08 | 1988-04-08 | 耳疾患用局所製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26367A true PH26367A (en) | 1992-06-01 |
Family
ID=13885215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38446A PH26367A (en) | 1988-04-08 | 1989-04-06 | Topical preparation for treating otopathy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5401741A (ja) |
| EP (1) | EP0337328B1 (ja) |
| JP (2) | JPH01258620A (ja) |
| KR (1) | KR0126471B1 (ja) |
| AT (1) | ATE109350T1 (ja) |
| AU (1) | AU614349B2 (ja) |
| CA (1) | CA1330946C (ja) |
| DE (1) | DE68917186T2 (ja) |
| DK (1) | DK175302B1 (ja) |
| HK (1) | HK196596A (ja) |
| HU (1) | HU00407A9 (ja) |
| IE (1) | IE65859B1 (ja) |
| IL (1) | IL89807A (ja) |
| NZ (1) | NZ228632A (ja) |
| PH (1) | PH26367A (ja) |
| ZA (1) | ZA892449B (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686095A (en) * | 1995-10-23 | 1997-11-11 | Price, Jr.; Francis W. | Method of treating canker sores |
| US5753269A (en) * | 1995-12-27 | 1998-05-19 | Bayer Corporation | Otic microbial combinations |
| US6022551A (en) * | 1998-01-20 | 2000-02-08 | Ethicon, Inc. | Antimicrobial composition |
| US5997893A (en) * | 1998-01-20 | 1999-12-07 | Ethicon, Inc. | Alcohol based anti-microbial compositions with cosmetic appearance |
| US6248343B1 (en) | 1998-01-20 | 2001-06-19 | Ethicon, Inc. | Therapeutic antimicrobial compositions |
| US5972358A (en) * | 1998-01-20 | 1999-10-26 | Ethicon, Inc. | Low tack lotion, gels and creams |
| US5912255A (en) * | 1998-02-27 | 1999-06-15 | Bussell; Letantia | Topical fluoroquinolone antibiotics combined with benzoyl peroxide |
| US6017912A (en) * | 1998-02-27 | 2000-01-25 | Bussell; Letantia | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle |
| JP5138128B2 (ja) * | 1998-08-21 | 2013-02-06 | 千寿製薬株式会社 | 水性液剤 |
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| US6676930B2 (en) * | 1999-11-28 | 2004-01-13 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US7064132B2 (en) * | 1999-11-28 | 2006-06-20 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis external |
| AU2001291219A1 (en) | 2000-09-25 | 2002-04-08 | Bayer Healthcare Llc | Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
| US20090215735A1 (en) * | 2002-02-25 | 2009-08-27 | Alcon, Inc. | Topical solution formulations containing a corticosteroid and a cyclodextrin |
| ES2552936T3 (es) | 2003-12-12 | 2015-12-03 | Otic Pharma Ltd. | Composiciones para el tratamiento del desordenes en el oído y métodos para el uso de los mismos |
| US8940321B2 (en) | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| WO2015031393A1 (en) | 2013-08-27 | 2015-03-05 | Otonomy, Inc. | Treatment of pediatric otic disorders |
| EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260416A (en) * | 1979-09-04 | 1981-04-07 | Allied Chemical Corporation | Amorphous metal alloy for structural reinforcement |
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| US4551456A (en) * | 1983-11-14 | 1985-11-05 | Merck & Co., Inc. | Ophthalmic use of norfloxacin and related antibiotics |
| JPS638333A (ja) * | 1986-06-30 | 1988-01-14 | Dai Ichi Seiyaku Co Ltd | 外用剤 |
| JP2558107B2 (ja) * | 1986-12-18 | 1996-11-27 | 第一製薬株式会社 | 外用剤 |
| CA1309024C (en) * | 1986-12-19 | 1992-10-20 | Hiromitsu Seki | Aqueous pharmaceutical composition containing s-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl -7-oxo-2,3,-dihydro-7h-pyridol[1,2,3,-de][1,4]benzoxazine -6-carboxylic acid |
-
1988
- 1988-04-08 JP JP63086378A patent/JPH01258620A/ja active Pending
-
1989
- 1989-03-30 CA CA000595126A patent/CA1330946C/en not_active Expired - Lifetime
- 1989-03-30 IL IL89807A patent/IL89807A/xx unknown
- 1989-04-03 ZA ZA892449A patent/ZA892449B/xx unknown
- 1989-04-06 KR KR1019890004498A patent/KR0126471B1/ko not_active IP Right Cessation
- 1989-04-06 NZ NZ228632A patent/NZ228632A/xx unknown
- 1989-04-06 PH PH38446A patent/PH26367A/en unknown
- 1989-04-07 EP EP89106215A patent/EP0337328B1/en not_active Expired - Lifetime
- 1989-04-07 DK DK198901681A patent/DK175302B1/da not_active IP Right Cessation
- 1989-04-07 JP JP1089379A patent/JP2573351B2/ja not_active Expired - Lifetime
- 1989-04-07 DE DE68917186T patent/DE68917186T2/de not_active Expired - Lifetime
- 1989-04-07 IE IE111889A patent/IE65859B1/en not_active IP Right Cessation
- 1989-04-07 AU AU32567/89A patent/AU614349B2/en not_active Expired
- 1989-04-07 AT AT89106215T patent/ATE109350T1/de not_active IP Right Cessation
-
1993
- 1993-04-12 US US08/048,959 patent/US5401741A/en not_active Expired - Lifetime
-
1995
- 1995-06-22 HU HU95P/P00407P patent/HU00407A9/hu unknown
-
1996
- 1996-10-24 HK HK196596A patent/HK196596A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU614349B2 (en) | 1991-08-29 |
| EP0337328B1 (en) | 1994-08-03 |
| KR0126471B1 (ko) | 1997-12-24 |
| IL89807A (en) | 1993-08-18 |
| JPH0334925A (ja) | 1991-02-14 |
| DE68917186T2 (de) | 1995-01-05 |
| NZ228632A (en) | 1991-10-25 |
| DK175302B1 (da) | 2004-08-16 |
| CA1330946C (en) | 1994-07-26 |
| ATE109350T1 (de) | 1994-08-15 |
| EP0337328A2 (en) | 1989-10-18 |
| HU00407A9 (en) | 1995-09-28 |
| ZA892449B (en) | 1989-12-27 |
| DE68917186D1 (de) | 1994-09-08 |
| JP2573351B2 (ja) | 1997-01-22 |
| JPH01258620A (ja) | 1989-10-16 |
| IE891118L (en) | 1989-10-08 |
| IE65859B1 (en) | 1995-11-29 |
| EP0337328A3 (en) | 1991-12-27 |
| DK168189D0 (da) | 1989-04-07 |
| DK168189A (da) | 1989-10-09 |
| HK196596A (en) | 1996-11-01 |
| KR890015742A (ko) | 1989-11-25 |
| US5401741A (en) | 1995-03-28 |
| AU3256789A (en) | 1989-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5401741A (en) | Topical preparation for treating otopathy | |
| US5843930A (en) | Method of treating otitis with ciprofloxacin-hydrocortisone suspension | |
| US6689302B2 (en) | Method of making an antimicrobial tympanostomy tube | |
| US3422186A (en) | Methods for the removal of cerumen and the methods for the treatment of ear disease | |
| Tom | Ototoxicity of common topical antimycotic preparations | |
| Naber | The role of quinolones in the treatment of chronic bacterial prostatitis | |
| EP1928439A2 (en) | Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear | |
| US6017912A (en) | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle | |
| Rohn et al. | Ototoxicity of topical agents | |
| Quesnel et al. | Synergism between chlorhexidine and sulphadiazine | |
| Roland et al. | Disorders of the external auditory canal. | |
| US20040126414A1 (en) | Methods and compositions for treating and preventing ear infections | |
| Lutz et al. | Ototoxicity of vancomycin: an experimental study in guinea pigs | |
| Fantin et al. | Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus | |
| EP0689832B1 (en) | Antibiotic preparation for aural application | |
| Leach et al. | Effect of topical fosfomycin on polymyxin B ototoxicity | |
| RU2297840C1 (ru) | Медьсеребросодержащее антимикробное средство для профилактики и лечения отита | |
| Gritz et al. | Topical Ofloxacin in the Treatment of Pseudomonas Keratitis in a Rabbit Mode | |
| Jang et al. | Evaluating the ototoxicity of topical piperacillin–tazobactam | |
| Bateman et al. | Effects of an enrofloxacin–silver sulfadiazine emulsion in the ears of rabbits with perforated tympanic membranes | |
| Sugar et al. | Treatment of experimental Pseudomonas corneal ulcers with enoxacin, a quinolone antibiotic | |
| Mainardi et al. | Activity of Isepamicin and Selection of Permeability Mutants to β-Lactams during Aminoglycoside Therapy of Experimental Endocarditis Due to Klebsiella pneumoniae CF104 Producing an Aminoglycoside Acetyltransferase 6′ Modifying Enzyme and a TEM-3 β-Lactamase | |
| Logas | Medical Management of Acute and Chronic Otitis | |
| Kato et al. | Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. | |
| US20080248135A1 (en) | Combination Therapy for Otitis with Antiseptic and pH Adjustment |